This issue is especially important considering that alterations in p53 (mutation, inactivation, etc.)are common events in different types cancers (For more information, see http://p53.free.fr/ and http://p53.bii.a-star.edu.sg/index.php) and are also major determinants in the therapeutic response to CDDP. The gene discussed is TP53; the disease is cancer.